CytoReason is an AI company developing a computational model of the human body, accurate enough to start replacing animal and human trials in drug development.
www.cytoreason.com
www.cytoreason.com
Location: Israel, Tel Aviv District, Tel Aviv-Yafo
Total raised: $100M
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.07.2024 | - | $80M | - |
| 20.09.2022 | - | $20M | - |
Mentions in press and media 17
| Date | Title | Description |
| 26.07.2024 | CytoReason: $80 Million Raised To Develop Computational Disease Models For Predictive Insights | CytoReason, a leader in developing computational disease models for predictive insights, announced it raised an aggregated $80 million from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific. CytoReason plans to use this funding to expa... |
| 20.07.2024 | CytoReason: Pioneering the Future of Drug Discovery with AI Innovation | In a groundbreaking move, Israeli startup CytoReason has secured a substantial $80 million in funding to bolster its AI model and establish a hub in Massachusetts. This significant investment marks a pivotal moment for the company, which sp... |
| 19.07.2024 | Israeli startup CytoReason raises $80M to expand AI model, open hub in Massachusetts | Photo: RyanKing999/Getty Images Israeli startup CytoReason, maker of a computation model to map and compare treatments, announced it secured $80 million in funding. Pfizer, OurCrowd, NVIDIA and Thermo Fisher Scientific participated in the r... |
| 17.07.2024 | CytoReason Raises $80M in Funding | CytoReason, a Tel Aviv, Israel-based company which specializes in developing computational disease models for predictive insights, raised an aggregated $80M. The amount was led by OurCrowd, NVIDIA (Nasdaq: NVDA), Pfizer (NYSE: PFE), and The... |
| 24.03.2022 | Poolbeg Pharma strikes deal with CytoReason for AI analysis | Clinical stage infectious disease pharmaceutical company Poolbeg Pharma has signed a deal with CytoReason for the artificial intelligence firm to provide analysis of its influenza disease progression data derived from human challenge study ... |
| 10.02.2022 | CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development | TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ -- CytoReason, a leading developer of computational disease models for efficient drug discovery and development, today announced the extension of its collaboration agreement with Pfizer. "Th... |
| 21.10.2021 | CytoReason Collaborates With Merck On Cancer Immunotherapy Drug | Using its proprietary computational disease models, CytoReason will help Merck understand the drug’s mechanism of action, identify patient populations and prioritize indications. CytoReason, an Israeli company developing computational disea... |
| 30.09.2021 | CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan's Top Pharmaceutical Companies | TOKYO and TEL AVIV, Israel, Sept. 30, 2021 /PRNewswire/ -- CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals International (SPI), a Japanese company pro... |
| 30.09.2021 | CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan’s Top Pharmaceutical Companies | CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals International (SPI), a Japanese company providing service and products to the pharmaceutical industry ... |
| 17.06.2021 | CytoReason Collaborates With Sanofi, Using Its AI Technology to Gain Better Understanding of Disease Mechanisms | The Focus of the Project Is to Tackle Asthma, a Major Chronic Condition Affecting More Than 340 Million People Globally CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, anno... |
Show more